An Open-Label, Depot Buprenorphine (RBP-6000) Treatment Extension Study in Subjects With Opioid Use Disorder
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid abuse
- Focus Adverse reactions
- Sponsors Indivior
- 27 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.
- 27 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 26 Sep 2016 New trial record